ArticleTranslational cancer research2026
KLF15-POU3F4 axis activates PI3K/AKT signaling to promote glioma progression.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioma is a highly aggressive brain tumor with poor prognosis, necessitating new biomarkers and therapeutic targets. This study aimed to explore the role of Pit-Oct-Unc class 3 homeobox 4 (POU3F4) in glioma using bioinformatics analysis and experimental verification. Methods: Bioinformatics analysis was performed using the public databases The Cancer Genome Atlas (TCGA) and Human Protein Atlas database to explore POU3F4 expression and prognosis in gliomas. Samples were collected from clinical glioma tissues, paracancerous tissues, and plasma of patients and healthy candidates. POU3F4 expression was examined using molecular biological methods, and its potential diagnostic value was assessed. Results: Bioinformatics analysis revealed that POU3F4 levels were increased in gliomas, and upregulated POU3F4 may be associated with poor prognosis. Additionally, clinical sample analysis confirmed that POU3F4 was overexpressed in glioma tissues and plasma samples, and its levels in glioma tissues were positively associated with those in the plasma. The receiver operating characteristic (ROC) curve demonstrated that POU3F4 levels in both tissue and plasma exhibited good diagnostic value for glioma. Conclusions: POU3F4 was upregulated in glioma and facilitated glioma cell growth and metastasis while suppressing apoptosis. KLF15 is its upstream transcription factor that positively regulates the expression of POU3F4. The KLF15-POU3F4 axis promotes glioma progression by activating the PI3K/AKT signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.